Rinri Therapeutics (‘Rinri’), a biotechnology company developing a novel cell-based therapy to restore hearing loss, is delighted to announce that it has secured, a grant from Innovate UK, the UK’s innovation agency. This grant will fund a £3.2 million project to further develop Rinri’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL) an area / a condition where there remains a significant global unmet need.

The project will be led by Rinri in collaboration with the Cell and Gene Therapy Catapult (CGTC), and the Universities of Sheffield and Nottingham. Over the course of the project, the CGTC will help establish a process and analytical tools for clinical trial manufacture of Rinri’s stem cell therapy for hearing loss, Sheffield University will further the nonclinical data package and Nottingham University will develop the necessary techniques for the first in human trial of Rinri’s cell-based therapy to restore hearing loss.

Read More.

Categories: Industry News